Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metast...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455922002133 |
| _version_ | 1828407162691387392 |
|---|---|
| author | Masafumi Yasunaga Hideaki Yahata Kaoru Okugawa Mototsugu Shimokawa Yumiko Maeda Emiko Hori Keisuke Kodama Hiroshi Yagi Tatsuhiro Ohgami Ichiro Onoyama Kazuo Asanoma Kiyoko Kato |
| author_facet | Masafumi Yasunaga Hideaki Yahata Kaoru Okugawa Mototsugu Shimokawa Yumiko Maeda Emiko Hori Keisuke Kodama Hiroshi Yagi Tatsuhiro Ohgami Ichiro Onoyama Kazuo Asanoma Kiyoko Kato |
| author_sort | Masafumi Yasunaga |
| collection | DOAJ |
| description | Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metastatic cervical cancer patients where bevacizumab was added to paclitaxel plus carboplatin. Materials and methods: A retrospective analysis was performed on 90 patients with recurrent, persistent, or metastatic cervical cancer mainly treated by paclitaxel plus carboplatin between 2005 and 2019 at our hospital. Data for the following clinicopathological variables were analyzed: (1) bevacizumab use; (2) histology; (3) disease presentation; (4) performance status; (5) prior chemotherapy containing platinum agent; (6) pelvic disease; (7) prior pelvic radiotherapy; (8) location of target lesions. Survival analysis was performed using Kaplan–Meier curves, log-rank tests, Wilcoxon tests, and Cox proportional hazards models combined with propensity score matching. Results: Adding bevacizumab to paclitaxel plus carboplatin showed significantly increased complete response to compared with that of non-users. In a Cox regression hazard model, bevacizumab use tended to show better OS though without statistically significance. After propensity score matching, adding bevacizumab to paclitaxel plus carboplatin showed a significant better OS by univariate analysis using Wilcoxon test, not by log-rank test. Conclusion: Adding bevacizumab to paclitaxel plus carboplatin showed a limited prognostic impact for recurrent, persistent or advanced cervical cancer patients in the real world. Further effective second-line treatments are needed to prolong OS of patients with recurrent, persistent or advanced cervical cancer. |
| first_indexed | 2024-12-10T11:21:28Z |
| format | Article |
| id | doaj.art-5b181dc2d426448d844742f516345960 |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-12-10T11:21:28Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-5b181dc2d426448d844742f5163459602022-12-22T01:50:54ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592022-09-01615818822Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancerMasafumi Yasunaga0Hideaki Yahata1Kaoru Okugawa2Mototsugu Shimokawa3Yumiko Maeda4Emiko Hori5Keisuke Kodama6Hiroshi Yagi7Tatsuhiro Ohgami8Ichiro Onoyama9Kazuo Asanoma10Kiyoko Kato11Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan; Corresponding author. Department of Gynecology and Obstetrics, Kyushu University Hospital, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan.Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanDepartment of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, JapanObjective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metastatic cervical cancer patients where bevacizumab was added to paclitaxel plus carboplatin. Materials and methods: A retrospective analysis was performed on 90 patients with recurrent, persistent, or metastatic cervical cancer mainly treated by paclitaxel plus carboplatin between 2005 and 2019 at our hospital. Data for the following clinicopathological variables were analyzed: (1) bevacizumab use; (2) histology; (3) disease presentation; (4) performance status; (5) prior chemotherapy containing platinum agent; (6) pelvic disease; (7) prior pelvic radiotherapy; (8) location of target lesions. Survival analysis was performed using Kaplan–Meier curves, log-rank tests, Wilcoxon tests, and Cox proportional hazards models combined with propensity score matching. Results: Adding bevacizumab to paclitaxel plus carboplatin showed significantly increased complete response to compared with that of non-users. In a Cox regression hazard model, bevacizumab use tended to show better OS though without statistically significance. After propensity score matching, adding bevacizumab to paclitaxel plus carboplatin showed a significant better OS by univariate analysis using Wilcoxon test, not by log-rank test. Conclusion: Adding bevacizumab to paclitaxel plus carboplatin showed a limited prognostic impact for recurrent, persistent or advanced cervical cancer patients in the real world. Further effective second-line treatments are needed to prolong OS of patients with recurrent, persistent or advanced cervical cancer.http://www.sciencedirect.com/science/article/pii/S1028455922002133BevacizumabCarboplatinDrug therapyPrognosisUterine cervical neoplasms |
| spellingShingle | Masafumi Yasunaga Hideaki Yahata Kaoru Okugawa Mototsugu Shimokawa Yumiko Maeda Emiko Hori Keisuke Kodama Hiroshi Yagi Tatsuhiro Ohgami Ichiro Onoyama Kazuo Asanoma Kiyoko Kato Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer Taiwanese Journal of Obstetrics & Gynecology Bevacizumab Carboplatin Drug therapy Prognosis Uterine cervical neoplasms |
| title | Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer |
| title_full | Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer |
| title_fullStr | Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer |
| title_full_unstemmed | Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer |
| title_short | Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer |
| title_sort | prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent persistent or metastatic cervical cancer |
| topic | Bevacizumab Carboplatin Drug therapy Prognosis Uterine cervical neoplasms |
| url | http://www.sciencedirect.com/science/article/pii/S1028455922002133 |
| work_keys_str_mv | AT masafumiyasunaga prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT hideakiyahata prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT kaoruokugawa prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT mototsugushimokawa prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT yumikomaeda prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT emikohori prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT keisukekodama prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT hiroshiyagi prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT tatsuhiroohgami prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT ichiroonoyama prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT kazuoasanoma prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer AT kiyokokato prognosticimpactofaddingbevacizumabtocarboplatinandpaclitaxelforrecurrentpersistentormetastaticcervicalcancer |